Regor Therapeutics

Focus: Regor Therapeutics is a China-based biotechnology company specializing in computer-accelerated rational drug discovery, leveraging computational approaches to identify novel therapeutics.

Oncology Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Regor Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Regor Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RGT-419B

Breast Cancer

Phase 1

Clinical Trials (1)

NCT06299124A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Phase 1

Help build intelligence for Regor Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to build foundational capabilities in computational drug discovery, a high-growth segment in biotech
Shanghai headquarters positions you at the center of China's biotech innovation ecosystem
Ground-floor role at a company pioneering computer-accelerated rational discovery, a differentiated scientific approach

Watch Out For

No active pipeline programs or clinical trials reported; development stage and timeline unclear
No hiring activity currently (0 active job postings), suggesting possible early formation or funding constraints

Generated by Claude from Regor Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RGT-419B

Breast Cancer

Phase 1

Clinical Trials (1)

NCT05304962FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Phase 1

RGT-490

Breast Cancer

Phase 1

Clinical Trials (1)

NCT07524322Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Phase 1